Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
CSPC Pharma taps R&D superstar in quest for new breakout drugs
Liu Yongjun’s drug commercialization experience and ties to multinational firms are urgently needed for his new employer’s ongoing transformation Key Takeaways: CSPC Pharma’s new R&D head Liu Yongjun engineered the…
Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Ascentage Pharma soars on deal with cancer drug competitor
The Chinese drug developer put a rocket booster under its share price after enlisting a Japanese rival as a new equity partner and unveiling plans for a U.S. listing Key…
Test results for new cancer drug take Akeso investors on wild ride
Shares in the Chinese pharmaceutical company swung back and forth as investors tried to make sense of clinical trial data for an immunotherapy drug billed as a potential world beater…
FAST NEWS: Lepu Biopharma to raise $32 million in share sale
The Latest: Innovative drug maker Lepu Biopharma Co. Ltd. (2157.HK) announced on Friday it will place up to 51.17 million shares, or about 2.99% of its overall issued share capital, for…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
Akeso marks profit milestone with swift rights issue
9926.HK
